Literature DB >> 14980986

Treatment of heparin-induced thrombocytopenia: a critical review.

Jack Hirsh1, Nancy Heddle, John G Kelton.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy that has a high rate of morbidity (thrombosis and amputation) and mortality. In the past, a number of different anticoagulants have been used to treat HIT in an attempt to prevent these complications. More recently, direct thrombin inhibitors have become popular. This systematic review summarizes the risk for thrombosis in HIT patients when heparin therapy is stopped; evidence of the efficacy of thrombin inhibitors in patients with HIT with and without thrombosis; evidence supporting the use of thrombin inhibitors in patients with a history of HIT who require a coronary intervention procedure; and the risk for bleeding when antithrombotic agents are used.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14980986     DOI: 10.1001/archinte.164.4.361

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  33 in total

1.  [Recommendations for the administration of conventional and new antithrombotic agents from the perspective of anesthesiology].

Authors:  W Gogarten; K Hoffmann; H Van Aken
Journal:  Unfallchirurg       Date:  2010-11       Impact factor: 1.000

2.  Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia.

Authors:  Janice McFarland; Andrew Lochowicz; Richard Aster; Bryan Chappell; Brian Curtis
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

3.  Heparin-induced thrombocytopenia: comparison between response to fondaparinux and lepirudin.

Authors:  Amani Al-Rossaies; Khalid M Alkharfy; Fakhar Al-Ayoubi; Abdulkareem Al-Momen
Journal:  Int J Clin Pharm       Date:  2011-10-16

4.  Safety and efficacy of the argatroban therapy during the early post-cardiac surgery period.

Authors:  Joo Heung Yoon; Robert W Yeh; Kyung Hun Nam; William D Hoffman; Arvind K Agnihotri; Ik-Kyung Jang
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

5.  Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR).

Authors:  John R Bartholomew; Marcie J Hursting
Journal:  J Thromb Thrombolysis       Date:  2005-06       Impact factor: 2.300

6.  Heparin-induced thrombocytopenia in a case of endovascular aneurysm coiling.

Authors:  V Gupta; R Tanvir; A Garg; S B Gaikwad; N K Mishra
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

Review 7.  Hemostatic abnormalities in critically ill patients.

Authors:  Marcel Levi; Suthesh Sivapalaratnam
Journal:  Intern Emerg Med       Date:  2014-12-24       Impact factor: 3.397

8.  Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.

Authors:  John R Bartholomew; Carolynn E Pietrangeli; Marcie J Hursting
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 9.  Low molecular weight heparin-induced skin necrosis-a systematic review.

Authors:  A E Handschin; O Trentz; H J Kock; G A Wanner
Journal:  Langenbecks Arch Surg       Date:  2004-11-27       Impact factor: 3.445

10.  Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries.

Authors:  Laura Elizabeth Happe; Eileen Marie Farrelly; Richard H Stanford; Matt William Sarnes
Journal:  J Thromb Thrombolysis       Date:  2007-11-24       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.